Navigation Links
Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
Date:4/29/2009

IP protection to our NeuroTrans(TM) program. The broad claims are designed to protect the use of our NeuroTrans(TM) CNS targeting peptides and the extensive range of potential uses of NeuroTrans(TM) in treating CNS disorders. We believe the intellectual property protections established by these patent allowances will significantly enhance our ability to form strong development collaborations with potential partners to advance NeuroTrans(TM) into clinical trials in neurodegenerative diseases."

About NeuroTrans(TM)

NeuroTrans(TM) is Raptor's proprietary receptor-associated protein ("RAP")-based technology program designed to deliver therapeutics across the blood-brain barrier ("BBB"), with the potential to provide safer, less intrusive, and more effective therapies to treat a wide variety of brain disorders. Preclinical studies indicate that radio-labeled NeuroTrans(TM) crosses the BBB through transcytosis, or the selective receptor-mediated transport of peptides and large proteins across the endothelial membrane in the BBB. NeuroTrans(TM) has also been conjugated to a variety of protein drugs, including enzymes and growth factors, without interfering with their therapeutic functions.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("Huntington's"), and aldehyde dehydrogenase ("ALDH2") deficiency.

Raptor's preclinical programs are based upon bioengineered novel dr
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... Brittenford ... independent schools, and other growing businesses across the United States, has announced that ... Resellers for the fifth consecutive year. , Based on company revenue and number ...
(Date:6/29/2015)... ... ... People across the country give their coworkers and families gifts all the time. From holiday ... how often do coworkers donate “life” to the husband of a coworker? For one VA ... (Wright-Thompson) told me her husband was on a donor list,” Glenshaw resident Kathi Dahl said. ...
(Date:6/29/2015)... ... June 29, 2015 , ... Assurex Health, a precision medicine ... and chronic pain conditions, has announced appointments to three key leadership roles, according ... Senior Vice President, Chief Financial Officer; Craig S. Lewis, Senior Vice President, Chief ...
(Date:6/29/2015)... , ... June 29, 2015 , ... The world’s fastest ... Virginia Aviation Museum to the Science Museum of Virginia. This iconic, supersonic stealth plane ... 2016. , “Suspending a supersonic jet from the ceiling of a historic train station ...
(Date:6/29/2015)... Detroit, MI (PRWEB) , ... June 29, 2015 , ... ... a perfect ten and have flawless skin all summer long and beyond. People ... 10 simple steps to slow the aging process, maintain an even skin tone, avoid ...
Breaking Medicine News(10 mins):Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:SR-71 Prepares for Flight to Science Museum of Virginia 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3
... Importance of Allergy Testing to Control Chronic ... ... Allergy and asthma specialists,from around the country will gather this week ... for,the Diagnosis and Management of Asthma. These guidelines are intended to,improve ...
... Studies have shown that surgery combined with Intraperitoneal Hyperthermic ... with peritoneal carcinoma (cancer of the lining of the ... cancer. , Researchers from Wake Forest University School of ... use of IPHC in treating peritoneal cancer that has ...
... WASHINGTON, March 14 Last night, the U.S.,Senate ... for,Legislative and Public Affairs for the U.S. Agency ... Bureau for Legislative and Public Affairs, Grieco will,manage ... public,and constituent groups to communicate the agency,s mission, ...
... scientists suggests a safer way to treat medulloblastoma, a ... found that one of the brains signaling pathways inhibits ... , The researchers discovered that three proteins, designated BMP2, ... and induced the malignant cells to develop into normal ...
... moved from colon, appendix , , FRIDAY, March 14 (HealthDay ... spread to the peritoneum -- the membrane lining the ... of chemotherapy can improve survival rates, Wake Forest University ... two Wake Forest studies presented at this week,s annual ...
... team of researchers in Bedford, Mass. has developed a ... detect signs of Alzheimer,s disease. , In the ... by the Optical Society of America, the team describes ... taken from different autopsies and correctly identified which samples ...
Cached Medicine News:Health News:NIH Asthma Guidelines Will Leave Sufferers Breathing Easier This Spring 2Health News:Researchers study new drug and indications for heated chemotherapy treatment 2Health News:Jeffrey J. Grieco Confirmed as USAID Assistant Administrator for Legislative and Public Affairs 2Health News:St. Jude finds signaling system that halts the growth of a childhood brain cancer 2Health News:St. Jude finds signaling system that halts the growth of a childhood brain cancer 3Health News:Combo Treatment Ups Survival When Cancer Spreads to Abdominal Lining 2Health News:Researchers use light to detect Alzheimer's 2Health News:Researchers use light to detect Alzheimer's 3
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: